To mark the second anniversary of the Oct. 7 attacks in Israel, the Jewish Insider team asked leading thinkers and ...

Kratos leads in defense tech with strong growth and contracts, but slim margins and high valuation limit upside for now. Read ...

Sanofi recently announced that its investigational radiopharmaceutical therapy, AlphaMedix™, met all primary efficacy endpoints in a Phase II trial for patients with unresectable or metastatic ...

MoonLake Immunotherapeutics recently announced that its Phase 3 VELA-2 trial for sonelokimab in hidradenitis suppurativa did not meet its primary goal due to a higher-than-expected placebo response, ...

TSMC is thriving amid unstoppable AI demand, with strong earnings, global expansion, and a massive cash position fueling long ...

New, high-quality research quantifying the powerful impact of federal non-defense research and development shows why the dramatic cuts to non-defense R&D funding proposed by the Trump Administration ...

The paradox of India’s education system: high graduation rates from ITIs, yet low placements, because students want to work ...

The Bison Economy is not just a vision — it’s a declaration that Canada’s next tech revolution will not come from its largest cities, but from its boldest province. Rooted in Indigenous strength, ...

Should public company pay be more like private equity fund pay? This analysis compares incentive structures, retention, and ...

Neurizon Therapeutics is free to advance the next clinical trial of its candidate to treat amyotrophic lateral sclerosis (ALS ...